Niacin As Secondary Prevention Of Coronary Artery Disease (NASPOCAD)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00431145
Recruitment Status : Unknown
Verified February 2007 by Ludwig-Maximilians - University of Munich. Recruitment status was: Recruiting
Aim of the study is to show additional effects of the combined therapy of niacin and statins analyzing number and function of EPCs and other stem cell populations and adiponectin as well as hsCRP levels in patients with CAD.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Be at least 18 years old, male or female
Have stable coronary artery disease (i.e. no acute event like myocardial infarction or PTCA less then 3 months ago)
LDL > 100 mg/dl
HDL < 50 mg/dl
Triglycerides < 400 mg/dl
No Nicotine abuse for at least 3 months
Statin-therapy for more than 4 weeks
Give a written informed consent
Have the ability to understand the requirements of the study, and agree and be able to return for the required assessments.
Women of childbearing potential, pregnancy or being lactating
Current participation in another clinical trial
Have other severe concurrent illness (e.g., active infection, malignancy)
Have a history of alcohol or drug abuse within 3 months of admission or factors making follow-up difficult or unlikely.
Have significant or unexplained liver dysfunction or chronic increased levels of transaminases (ALT, AST)
Suffer from myopathy, active peptic disease or arterial bleeding
Have a known hypersensitivity against niacin or statins
Are actually treated with any of itraconazole, ketoconazole, HIV-Protease-Inhibitors, erythromycin, clarithromycin, telithromycin, nefazodone.